Anavex (AVXL) Treasurer Sandra Boenisch Receives 95,000 Option Awards

What Happened
Sandra Boenisch, Anavex Life Sciences Corp. (AVXL) Principal Financial Officer & Treasurer, had four previously unvested option awards (totaling 95,000 options) accelerate and become vested/exercisable on 2026-09-24. The awards reported as acquired (derivative) at $0.00 reflect vesting, not an exercise or sale. The option lots are: 20,000 @ $10.09 (granted 6/27/2022), 25,000 @ $8.57 (3/31/2023), 25,000 @ $5.36 (2/20/2024) and 25,000 @ $8.58 (3/31/2025).

Key Details

• Transaction date: 2026-09-24 (reported on Form 4 filed 2026-09-28). Filing appears within the SEC Form 4 reporting timeframe.
• Transaction type: Derivative acquisition via vesting (code A); acquisition price shown $0.00 because awards vested rather than being exercised.
• Option counts and exercise prices: 20,000 @ $10.09; 25,000 @ $8.57; 25,000 @ $5.36; 25,000 @ $8.58 (total 95,000).
• Shares owned after transaction: Not specified in this filing.
• Footnote: Vesting was triggered by a "change in control" following the issuer’s 2026 Annual Meeting (see issuer 8‑K filed 9/28/2026); these awards were performance‑based and had not been previously reported because they were unvested.
• No exercise or sale reported here—this filing documents acceleration/vesting only.

Context
This was an acceleration/vesting event (not a market purchase or sale). Vesting makes the options exercisable (which would require paying the exercise prices to convert to stock) and may have tax consequences when exercised; it does not by itself indicate the insider bought or sold shares. Monitor future Form 4s for any exercises or open‑market sales if you track insider conviction.